$10.48
+0.67 (+6.83%)
Open$9.22
Previous Close$9.81
Day High$10.58
Day Low$9.08
52W High$19.15
52W Low$3.92
Volume—
Avg Volume8.35M
Market Cap84.70M
P/E Ratio2.59
EPS$3.13
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
-32.8% upside
Current
$10.48
$10.48
Target
$7.04
$7.04
$5.84
$7.04 avg
$9.41
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 76.74M | 61.97M | 4.60M |
| Net Income | 20.77M | 15.09M | -132,709 |
| Profit Margin | 27.1% | 25.7% | -2.9% |
| EBITDA | 24.11M | 18.49M | -214,542 |
| Free Cash Flow | — | — | -85,981 |
| Rev Growth | +23.9% | +23.9% | -8.7% |
| Debt/Equity | 0.04 | 0.04 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |